2015 American Transplant Congress
Rituximab With Intravenous Immune Globulin in Sensitized Patients Awaiting Heart Transplant: Does It Work?
Cedars-Sinai Heart Institute, Los Angeles, CA.
Purpose: Highly sensitized heart transplant (HTx) recipients with donor specific antibodies (DSA) are at increased risk of rejection and death. Rituximab with Intravenous Immune Globulin…2015 American Transplant Congress
CTLA4Ig Administered During T-Cell Priming Negates de novo Alloantibody Responses and Modulates Recall Antibody Production
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Arcadia, CA.
Background CTLA4Ig (Belatacept) is a novel anti-rejection therapy aimed at costimulatory blockade. Clinical data suggest that post-transplant alloantibody formation is also reduced in patients treated…2015 American Transplant Congress
Comparison of Efficacy and Renal Function in KidneyTransplant Recipients Receiving Tacrolimus (TAC)-Based Immunosuppressive Regimens in Combination With Everolimus (EVR) or Mycophenolate (MPA)
1Nephrology, Hospital do Rim UNIFESP, Sao Paulo, Brazil; 2Pathology, UNIFESP, Sao Paulo, Brazil.
Introduction: Acute rejection and renal function are associated with long-term renal allograft survival. We evaluated these outcomes in patients receiving reduced TAC exposure combined with…2015 American Transplant Congress
Pharmacokinetics of Mycophenolic Acid (MPA) in Elderly Compared to Young Recipients in the First Year After Renal Transplantation. Data from the NEverOLd Trial
Elderly (≥60years) recipients are nowadays receiving renal transplants more frequently. The pharmacokinetics studies (PK) of immunosuppressive drugs in healthy volunteers, rarely, if ever, include old…